AUROPHARMA.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 18:59):

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India...

Stats
本日の出来高	1.13M
平均出来高	2.08M
時価総額	665.69B
EPS	INR0 ( 2024-02-11 )
次の収益日	( INR14.00 ) 2024-05-25
Last Dividend	INR3.00 ( 2023-02-17 )
Next Dividend	INR0 ( N/A )
P/E	24.05
ATR14	INR0.793 (0.07%)

ボリューム相関

長: -0.10 (neutral)

短: 0.32 (neutral)

Signal:(29.913) Neutral

Aurobindo Pharma Limited 相関

10 最も正の相関
SETF10GILT.NS	0.946
IZMO.NS	0.936
ADORWELD.NS	0.933
ANMOL.NS	0.927
GTNTEX.NS	0.92
ANURAS.NS	0.918
FOCUS.NS	0.918
TIIL.NS	0.917
GISOLUTION.NS	0.914
KIRLOSIND.NS	0.913

10 最も負の相関
STARTECK.NS	-0.883
GENESYS.NS	-0.878
EASTSILK.NS	-0.871
SEYAIND.NS	-0.871
ORTINLAB.NS	-0.864
DEEPINDS.NS	-0.862
GRMOVER.NS	-0.859
KOHINOOR.NS	-0.856
CLNINDIA.NS	-0.853
ESABINDIA.NS	-0.852

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aurobindo Pharma Limited 相関 - 通貨/商品

0.29
( neutral )

0.44
( neutral )

0.29
( neutral )

0.37
( neutral )

-0.72
( moderate negative )

-0.23
( neutral )

Aurobindo Pharma Limited 財務諸表

Annual	2022
収益:	INR246.17B
総利益:	INR133.24B (54.12 %)
EPS:	INR32.90

FY	2022
収益:	INR246.17B
総利益:	INR133.24B (54.12 %)
EPS:	INR32.90

FY	2022
収益:	INR233.67B
総利益:	INR132.26B (56.60 %)
EPS:	INR45.19

FY	2021
収益:	INR245.58B
総利益:	INR146.55B (59.68 %)
EPS:	INR91.05

Financial Reports:

No articles found.

Aurobindo Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR3.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Aurobindo Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.12 - low (37.00%) | Divividend Growth Potential Score: 4.13 - Stable (17.30%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.150	2001-09-12
Last Dividend	INR3.00	2023-02-17
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	42	--
Total Paid Out	INR38.23	--
Avg. Dividend % Per Year	0.47%	--
Score	2.85	--
Div. Sustainability Score	4.12
Div.Growth Potential Score	4.13
Div. Directional Score	4.13	--

Next Divdend (Est)
(2024-10-01)

INR0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

2.85

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.25	0.36%
2019	INR2.50	0.34%
2020	INR4.25	0.93%
2021	INR4.50	0.49%
2022	INR6.00	0.82%
2023	INR3.00	0.69%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TCI.NS	Dividend Junior	2023-07-25	Semi-Annually	23	0.70%
OBEROIRLTY.NS	Dividend Junior	2023-06-21	Sporadic	14	0.19%
INFOBEAN.NS	Dividend Junior	2023-07-21	Annually	7	0.37%
CONCOR.NS	Dividend Knight	2023-09-18	Semi-Annually	23	0.89%
SCI.NS	Dividend Junior	2023-09-01	Sporadic	22	0.25%
MALLCOM.NS	Dividend Junior	2023-09-04	Annually	3	0.20%
GOKEX.NS	Dividend Junior	2023-09-13	Sporadic	20	0.07%
AUTOAXLES.NS	Dividend Junior	2023-07-27	Annually	22	0.72%
TRENT.NS	Dividend Junior	2023-05-25	Annually	21	0.10%
PIDILITIND.NS	Dividend Junior	2023-07-27	Annually	23	0.29%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.100	1.500	7.99	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.101	1.500	9.99	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	15.99	1.000	5.19	5.19	[3 - 30]
operatingCashFlowPerShareTTM	51.10	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	25.58	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.548	1.000	4.20	4.20	[0.2 - 0.8]
operatingProfitMarginTTM	0.148	1.000	9.03	9.03	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	23.72	1.000	7.70	0	[1 - 100]
returnOnEquityTTM	0.101	2.50	10.00	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	25.58	2.00	1.474	10.00	[0 - 30]
dividendYielPercentageTTM	0.401	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	51.10	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.409	1.500	-6.06	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.109	1.000	9.79	0	[0.1 - 0.5]
Total Score				4.13

Aurobindo Pharma Limited

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.